LUSTAH SAS SAS

About LUSTAH SAS SAS

Matthieu Frechin is a central governance figure at Vetoquinol, the listed animal-health company headquartered in France and traded on Euronext Paris. He currently serves as Chairman of Vetoquinol SA and is also Chairman of LUSTAH SAS, a holding entity connected to the group. Public governance materials and executive databases consistently place him at the core of Vetoquinol’s leadership and ownership structure. His career at Vetoquinol shows a long and steady progression through senior operational and executive roles. Available sources indicate that he was appointed Chief Operating Officer in 2006, then Chief Executive Officer in 2009, effective in 2010, and later became Chairman and CEO in 2023. This trajectory suggests deep institutional knowledge of the company, its markets, and the operational challenges of managing an international veterinary pharmaceutical business. Frechin’s academic background reinforces that profile. He holds a Doctor of Pharmacy degree from the University of Nancy and also earned a postgraduate diploma in industrial systems engineering. That combination of scientific training and industrial expertise helps explain his management style, which appears to balance innovation, regulatory discipline, manufacturing efficiency, and commercial execution. At group level, he is associated with a governance model built around both listed-company oversight and holding-company coordination. Recent AMF filings identify LUSTAH SAS as a holding linked to Vetoquinol and note transactions carried out under that entity, underlining its relevance within the group’s capital structure and executive framework. Overall, Matthieu Frechin’s expertise spans corporate governance, strategic leadership, veterinary pharmaceuticals, and the management of holding structures and unlisted subsidiaries. His profile is that of a seasoned executive with a long-term commitment to Vetoquinol’s growth, international development, and shareholder-value creation.